Azeliragon|603148-36-3|(阿齐瑞格; TTP488; PF-04494700)-陌孚医药/Medlife

您当前的位置：

Azeliragon (Synonyms: 阿齐瑞格; TTP488; PF-04494700)

目录号: PL09422 纯度: ≥99%

CAS No. :603148-36-3

商品编号	规格	价格	会员价
PL09422-5mg	5mg	¥2101.82	请登录
PL09422-10mg	10mg	¥3461.82	请登录
PL09422-50mg	50mg	¥12240.00	请登录
PL09422-100mg	100mg	¥19781.82	请登录
PL09422-200mg	200mg	询价	询价
PL09422-500mg	500mg	询价	询价
PL09422-10mM*1mLinDMSO	10mM*1mLinDMSO	¥2460.36	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Azeliragon
中文别名	阿齐瑞格;3-[4-[2-丁基-1-[4-(4-氯苯氧基)苯基]-1H-咪唑]苯氧基]-N,N-二乙基-1-丙胺;大孔弱酸性阳离子交换树脂;氯丁胶乳
英文名称	Azeliragon
英文别名	3--4--2-Butyl-1--4--4-chlorphenoxy-phenyl--1H-imidazol-4-yl-phenoxy--N-N-diethylpropan-1-amin;Azeliragon;1-PROPANAMINE, 3-[4-[2-BUTYL-1-[4-(4-CHLOROPHENOXY)PHENYL]-1H-IMIDAZOL-4-YL]PHENOXY]-N,N-DIETHYL-;TTP488;[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-methanol;[3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethylamine;[3-(4-{2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1H-imidazole-4-yl}-phenoxy)-propyl]-diethyl-amine;3-(hydroxymethyl)phenylboronic acid pinacol ester;N-[3-[4-[2-Butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl]phenoxy]propyl]-N,N-diethylamine
Cas No.	603148-36-3
分子式	C₃₂H₃₈N₃O₂Cl
分子量	532.12
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情

Azeliragon (TTP488) 是一种生物可利用的晚期糖基化终产物 (RAGE) 受体抑制剂，可缓解轻度阿尔茨海默病 (AD) 的发展。Azeliragon 还可穿过血脑屏障 (BBB)。

生物活性

Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB).

性状

Solid

体外研究(In Vitro)

Azeliragon (4 nM; 16 hours; T cells) treatment inhibits of wild type mice (WT) but not the deletion of the receptor (RAGE-/- mice) T cells and significant reduction in the production of IFN-γ. has not independently confirmed the accuracy of these methods. They are for reference only.Cell Viability Assay

体内研究(In Vivo)

Azeliragon (100 mcg/d; intraperitoneal injection; every day) treatment reduces syngeneic islet graft and islet allograft in NOD and B6 mice (Islets were isolated from young prediabetic NOD/LtJ mice and transplanted into NOD mice with spontaneous diabetes; islets were isolated from WT BALB/c mice and transplanted into B6 mice with diabetes). has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Burstein AH, et al. Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis. Clin Pharmacol Drug Dev. 2019 May;8(4):426-435.
[2]. Bongarzone S, et al. Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective. J Med Chem. 2017 Sep 14;60(17):7213-7232.

溶解度数据	In Vitro: DMSO : 50 mg/mL (93.96 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation